1. Escalating de-escalation in breast cancer treatment

   • Virgilio Sacchini
   • Larry Norton

   Editorial 28 July 2022 Pages: 85 - 90

2. Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation

   • Lingmiao Kong
   • Ying Xiong
   • Wei Zhang

   Preclinical study 28 July 2022 Pages: 91 - 103

   

3. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

   • Minhong Tang
   • Shane O’Grady
   • Michael J. Duffy

   Preclinical study Open access 30 July 2022 Pages: 105 - 115

   

4. Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors

   • J. W. Ankersmid
   • F. K. Lansink Rotgerink
   • C. H. C. Drossaert

   Preclinical study Open access 30 July 2022 Pages: 117 - 125

   

5. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

   • Joyce O’Shaughnessy
   • Adam Brufsky
   • Javier Cortés

   Clinical trial Open access 11 May 2022 Pages: 127 - 139

   

6. Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors

   • Rachel A. Freedman
   • Anna C. Revette
   • Mara A. Schonberg

   Clinical trial 30 July 2022 Pages: 141 - 152

   

7. Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system

   • Debra T. Linfield
   • Michael B. Rothberg
   • Kathryn A. Martinez

   Epidemiology 16 July 2022 Pages: 153 - 160

8. Non-invasive predictors of axillary lymph node burden in breast cancer: a single-institution retrospective analysis

   • Victoria Ngai
   • Justina Cheh Juan Tai
   • Muneer Ahmed

   Epidemiology Open access 21 July 2022 Pages: 161 - 169

   

9. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

   • Henry G. Kaplan
   • Judith A. Malmgren
   • Mary K. Atwood

   Epidemiology Open access 22 July 2022 Pages: 171 - 180

   

10. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy

    • Anna Weiss
    • Claire King
    • Tari A. King

    Epidemiology 28 July 2022 Pages: 181 - 189

    

11. A prognostic survival model for women diagnosed with invasive breast cancer in Queensland, Australia

    • Peter D Baade
    • Helen Fowler
    • Joanne F Aitken

    Epidemiology Open access 28 July 2022 Pages: 191 - 200

    

12. Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation

    • Ying Wang
    • Megan E. Tesch
    • Caroline A. Lohrisch

    Epidemiology 30 July 2022 Pages: 201 - 208

    

13. Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study

    • Lauren McVicker
    • Christopher R. Cardwell
    • Úna C. McMenamin

    Epidemiology Open access 31 July 2022 Pages: 209 - 221